541 i de to fase III forsøg (pivotal studier), RESIST- 1 og RESIST- 2 været behandlet med 500 mg/ 200 mg to gange dagligt i mindst 48 uger.
14 the RESIST-1 and RESIST-2 Phase III pivotal trials, have been treated with 500 mg/ 200 mg twice daily for at least 48 weeks.